Holst Helle, Eldrup Ebbe, Guldstad Nana Harriet, Bülow Hans Henrik, Christensen Hanne Rolighed
Klinisk Farmakologisk Afdeling, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 København NV, Denmark.
Ugeskr Laeger. 2012 Jun 4;174(23):1598-602.
Metformin (MET) is the first-line agent in treatment of type 2 diabetes. However, MET has been associated with lactic acidosis (MALA), a potential but rare complication which has influenced treatment strategies in decades. Recently, guidelines have been changed in regards of age and heart failure and the contradiction of chronic renal impairment has been debated. This article identifies potential risk groups and situations that would benefit from a temporary interruption in the MET treatment.
二甲双胍（MET）是治疗2型糖尿病的一线药物。然而，MET与乳酸酸中毒（MALA）有关，这是一种潜在但罕见的并发症，几十年来一直影响着治疗策略。最近，关于年龄和心力衰竭的指南已经改变，慢性肾功能损害的矛盾也一直存在争议。本文确定了可能受益于暂时中断MET治疗的潜在风险群体和情况。
